RE:RE:RE:RE:RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024As for Pelareorep in breast cancer, the SeekingAlpha ghost writer had the temerity in trying to criticize the findings of PrECOG, a not-for-profit cancer research group formed to to support the overall purpose of the ECOG-ACRIN Cancer Research Group, who in their own are a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer.
https://www.precogllc.org/
https://ecog-acrin.org/about-us/
PrECOG conducted the ONCY pelareorep in breast cancer study, analyzed the data and presented their findings at ASCO 2023 in a podium presentation. Not ONCY. And PrECOGs complete findings were published online for all to see (see lin). Patients aged from 38 to 74 years of age. Too bad the SeekingAlpha ghost writer misinterpreted these facts as well.
https://d1io3yog0oux5.cloudfront.net/_fef86a905a9097048e2f859d543797f6/oncolyticsbiotech/db/343/2625/pdf/Abs1012_Clark+et+al_Draft+v21+15May2023.pdf